About
Technology
Issues
FAQ
Links
Official Page
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.